Wayne Hummer Investments L.L.C. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 37.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,896 shares of the medical research company’s stock after purchasing an additional 789 shares during the quarter. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $499,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. TrimTabs Asset Management LLC raised its holdings in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC raised its holdings in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after acquiring an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its holdings in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares in the last quarter. American Beacon Advisors Inc. purchased a new stake in shares of Amgen during the 1st quarter worth approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new stake in shares of Amgen during the 1st quarter worth approximately $121,000. Institutional investors and hedge funds own 78.20% of the company’s stock.
Amgen Inc. (AMGN) traded down $1.65 during midday trading on Monday, hitting $172.35. The company’s stock had a trading volume of 1,927,300 shares, compared to its average volume of 3,255,177. The company has a market capitalization of $125,110.00, a PE ratio of 13.70, a P/E/G ratio of 2.50 and a beta of 1.37. Amgen Inc. has a 52 week low of $138.83 and a 52 week high of $191.10. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.02 earnings per share. sell-side analysts predict that Amgen Inc. will post 12.66 earnings per share for the current year.
Amgen announced that its board has authorized a share buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a dividend of $1.15 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 annualized dividend and a dividend yield of 2.67%. Amgen’s dividend payout ratio (DPR) is currently 41.55%.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
Several analysts recently weighed in on the company. Royal Bank Of Canada began coverage on Amgen in a report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target on the stock. Bank of America Corporation lifted their price target on Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price target on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $196.00 price target (up from $189.00) on shares of Amgen in a research note on Friday, October 6th. Finally, Mizuho restated a “buy” rating and issued a $198.00 target price on shares of Amgen in a research report on Friday, October 6th. Thirteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Amgen has an average rating of “Buy” and a consensus target price of $190.03.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/13/amgen-inc-amgn-holdings-raised-by-wayne-hummer-investments-l-l-c.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.